文献速递新发突发、热带与寄生虫病

可溶性尿激酶型纤溶酶原激活物受体作为乌干达儿童重症和致死性疟疾风险的预后标志物

Soluble Urokinase-Type Plasminogen Activator Receptor as a Prognostic Marker of Ugandan Children at Risk of Severe and Fatal Malaria.
PubMed 文献 · Clin Infect Dis · 2023-01-01

在乌干达金贾连续纳入1226例就诊的发热疟疾患儿,检测血浆suPAR水平。39例(3.2%)院内死亡,死亡患儿suPAR显著高于存活者(P<.0001)。suPAR预测院内死亡的AUROC为0.92,加入LODS后AUROC从0.93提升至0.97(P<.0001)。

要点

  • 就诊时suPAR可识别重症和致死性疟疾风险患儿。
  • suPAR预测院内死亡AUROC 0.92(95%CI .91-.94)。
  • suPAR加入LODS后AUROC由0.93升至0.97(P<.0001)。

核心结论

  • 就诊时检测suPAR可识别重症和致死性疟疾风险患儿,加入临床评分可改善死亡风险识别与分诊,suPAR可用即时检测方法检测,现可在前瞻性试验中评估。

研究设计与样本

  • 在乌干达金贾医院连续纳入就诊的发热疟疾患儿,检测血浆suPAR水平,评估其预测院内死亡的准确性及能否改善经验证的Lambaréné器官功能障碍评分(LODS)。

主要发现

  • 1226例疟疾患儿中39例(3.2%)死亡,死亡患儿就诊时suPAR浓度显著高于存活者(P<.0001)。
  • suPAR水平与疾病严重程度相关(LODS 0 vs 1,P=.001;1 vs 2,P<.001;2 vs 3、0 vs 2、1 vs 3和0 vs 3,P<.0001)。
  • suPAR预测院内死亡的AUROC为0.92(95%CI .91-.94)。
  • LODS的AUROC为0.93(95%CI .91-.94),加入suPAR后AUROC为0.97(95%CI .96-.98),P<.0001。

关键数值与推荐

  • suPAR预测院内死亡AUROC 0.92(95%CI .91-.94)。
  • LODS AUROC 0.93(95%CI .91-.94),加suPAR后AUROC 0.97(95%CI .96-.98),P<.0001。

临床怎么用

  • 原文结论认为就诊时检测suPAR可识别重症和致死性疟疾风险患儿,加入临床评分可改善死亡风险识别与分诊,suPAR可用即时检测方法检测并可在前瞻性试验中评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current malaria diagnostic tests do not reliably identify children at risk of severe and fatal infection. Host immune and endothelial activation contribute to malaria pathogenesis. Soluble urokinase-type plasminogen activator receptor (suPAR) is a marker of these pathways. We hypothesized that measuring suPAR at presentation could risk-stratify children with malaria. METHODS: Plasma suPAR levels were determined in consecutive febrile children with malaria at presentation to hospital in Jinja, Uganda. We evaluated the accuracy of suPAR in predicting in-hospital mortality, and whether suPAR could improve a validated clinical scoring system (Lambaréné Organ Dysfunction Score [LODS]). RESULTS: Of the 1226 children with malaria, 39 (3.2%) died. suPAR concentrations at presentation were significantly higher in children who went on to die than in those who survived (P < .0001). suPAR levels were associated with disease severity (LODS: 0 vs 1, P = .001; 1 vs 2, P < .001; 2 vs 3, 0 vs 2, 1 vs 3, and 0 vs 3, P < .0001). suPAR concentrations were excellent predictors of in-hospital mortality (area under the receiver operating characteristic curve [AUROC], 0.92 [95% confidence interval {CI}, .91-.94]). The prognostic accuracy of LODS (AUROC, 0.93 [95% CI, .91-.94]) was improved when suPAR was added (AUROC, 0.97 [95% CI, .96-.98]; P < .0001). CONCLUSIONS: Measuring suPAR at presentation can identify children at risk of severe and fatal malaria. Adding suPAR to clinical scores could improve the recognition and triage of children at risk of death. suPAR can be detected with a point-of-care test and can now be evaluated in prospective trials.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Stefanova V, Ngai M, Weckman AM, et al. Soluble Urokinase-Type Plasminogen Activator Receptor as a Prognostic Marker of Ugandan Children at Risk of Severe and Fatal Malaria. Clin Infect Dis. 2023. PMID: 35675322. doi:10.1093/cid/ciac457

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。